一种耐火性活体状血管病,伴随着甲四酸降解酶基因多态性,成功地用高压氧气疗法治疗
Sang-Hoon Lee1, Yoonsuk Lee2, Eung Ho Choi3
1Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea.
具有MTHFR基因多态性的耐火活体血管病变 (LV) 可能具有挑战性. 高压氧气疗法 (HBOT) 在一个耐常规治疗的患者中显示出显著的愈合,这表明其作为一个可行的选择的潜力.
科学领域:
- 皮肤病学 皮肤病学
- 血管医学 血管医学
- 遗传学 是一个遗传学.
背景情况:
- 活体血管病变 (LV) 是一种慢性凝血障碍,导致下肢疼痛.
- 甲基四基叶酸减少酶 (MTHFR) 基因多态性与凝血病有关,并可能使LV严重程度恶化.
- 目前用于LV的治疗方法,包括抗炎和免疫抑制剂,缺乏共识的第一线方法,并且可能是无效的.
研究的目的:
- 报告一个具有MTHFR基因多态性的耐火活体血管病变 (LV) 病例.
- 为了评估高压氧化疗 (HBOT) 在治疗耐药的LV病例中的疗效.
主要方法:
- 治疗了一名63岁的女性患者,患有耐火性LV和确定的MTHFR基因多态.
- 标准治疗 (托西菲林,阿司匹林,皮质类固醇,抗胰岛素,抗生素) 在六个月内失败.
- 高压氧疗法 (HBOT) 在2.0 ATA下进行120分钟,每周三次.
主要成果:
- 显著的愈开始在4个HBOT疗程后.
- 皮肤病变在13次HBOT疗程后几乎完全愈合.
- 在八个月的随访期间,没有观察到皮肤的复发.
结论:
- 高压氧疗法 (HBOT) 在治疗具有MTHFR基因多态性的耐火性活体血管病变 (LV) 中表现出显著的有效性.
- 在严重和耐治疗的LV病例中,HBOT可能是一个有价值的治疗选择.
- 这一案例提供了支持HBOT作为耐火性LV的潜在治疗方法的证据.
更多相关视频
09:52Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
